Annual rate of change in % predicted FEV1 Subgroup: over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Transmission‐related outcomes: hospitalization ‐ Number or proportion of hospital admissions · adults and children with cystic fibrosis
Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Ferritin: final or change (µg/L) · adults and children with CKD
1 finding from 1 review
Intervention not reported
TSAT: final or change (%) · adults and children with CKD
1 finding from 1 review
Intervention not reported
HCT (%) · adults and children with CKD
1 finding from 1 review
Intervention not reported
ESA dose: final or change · adults and children with CKD
1 finding from 1 review
Intervention not reported
eGFR: final or change (mL/min) · adults and children with CKD
1 finding from 1 review
Intervention not reported
Number achieving target Hb or increase ≥1 g/dL · adults and children with CKD
The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).
1 finding from 1 review
Intervention not reported
Hb: final or change (g/dL) · adults and children with CKD
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review